Skip Nav Destination
Issues
1 April 2007
-
Cover Image
Cover Image
Pymol diagrams showing binding interactions between the NH2-terminal ATP-binding site of human HSP90α and the 3,4-diarylpyrazole resorcinol VER-49009 (upper) and 3,4-diarylisoxazole resorcinol VER-50589 (middle). Hydrogen bonds (dotted blue lines), amino acid residues involved (green), water molecules (cyan-coloured spheres) and residues in van der Waals contact (cyan). Also shown (lower) are orthogonal views of the bound structures of VER-49009 (cyan), VER-50589 (yellow) and ADP (green), overlaid by superimposition of the HSP90 NH2-domains from the crystal structures of the individual complexes. Protein X-ray crystallography was determined at 2.1 and 2.0 resolution for VER-49009 and VER-50589, respectively. VER-50589 exhibits the tightest binding of any synthetic small molecule yet reported, shows proof of concept for target inhibition and antitumor activity in an animal model, and illustrates the therapeutic potential of this new series of HSP90 inhibitors. For details, see Sharp et al. in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Editorial/Perspectives
Drug Development Series: Review
Review
Research Articles: Therapeutics, Targets, and Development
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Swee Y. Sharp; Chrisostomos Prodromou; Kathy Boxall; Marissa V. Powers; Joanna L. Holmes; Gary Box; Thomas P. Matthews; Kwai-Ming J. Cheung; Andrew Kalusa; Karen James; Angela Hayes; Anthea Hardcastle; Brian Dymock; Paul A. Brough; Xavier Barril; Julie E. Cansfield; Lisa Wright; Allan Surgenor; Nicolas Foloppe; Roderick E. Hubbard; Wynne Aherne; Laurence Pearl; Keith Jones; Edward McDonald; Florence Raynaud; Sue Eccles; Martin Drysdale; Paul Workman
MAP-ing glioma invasion: Mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival
Tim Demuth; Linsey B. Reavie; Jessica L. Rennert; Mitsutoshi Nakada; Satoko Nakada; Dominique B. Hoelzinger; Christian E. Beaudry; Amanda N. Henrichs; Eric M. Anderson; Michael E. Berens
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens
Lorenzo Daniele; Luigia Macrì; Marina Schena; Diego Dongiovanni; Lisa Bonello; Enrico Armando; Libero Ciuffreda; Oscar Bertetto; Gianni Bussolati; Anna Sapino
Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib
Peter Pyrko; Adel Kardosh; Yen-Ting Liu; Nathaniel Soriano; Wenyong Xiong; Robert H. Chow; Jasim Uddin; Nicos A. Petasis; Austin K. Mircheff; Robert A. Farley; Stan G. Louie; Thomas C. Chen; Axel H. Schönthal
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer
Qing Zhang; Neil E. Bhola; Vivian Wai Yan Lui; Doris R. Siwak; Sufi M. Thomas; Christopher T. Gubish; Jill M. Siegfried; Gordon B. Mills; Dong Shin; Jennifer Rubin Grandis
Inhibition of nuclear factor-κB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation
Yasuhisa Oida; Began Gopalan; Ryo Miyahara; Cynthia D. Branch; Paul Chiao; Sunil Chada; Rajagopal Ramesh
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.